Customize your JAMA Network experience by selecting one or more topics from the list below.
A JAMA THEME ISSUE
Edited by Phil B. Fontanarosa, MD, MBA, and Helene M. Cole, MD
Men with overactive bladder and other lower urinary tract symptoms are often treated with an antimuscarinic agent or an α-adrenergic receptor antagonist; however, monotherapy is not always effective. In a randomized 12-week trial, Kaplan and colleagues investigated the efficacy and safety of tolterodine extended release (an antimuscarinic), tamsulosin (an α-adrenergic receptor antagonist), both drugs, or placebo in men with overactive bladder and benign prostatic hypertrophy. The authors found that men who received combination therapy were significantly more likely to report treatment benefit than men receiving either monotherapy or placebo. All active treatments were well tolerated and the incidence of acute urinary retention was low.
This Week in JAMA . JAMA. 2006;296(19):2289. doi:10.1001/jama.296.19.2289
Create a personal account or sign in to: